Viral respiratory tract infections commonly cause hospitalizations, economic losses, morbidity and mortality in the US and worldwide. Influenza A virus (lAV), paramyxoviruses, rhinoviruses, human coronaviruses (HCoV), and other emerging, highly pathogenic respiratory viruses are a major global public health threat. Importantly, viral lung disease severity can range from mild self-limited infections to pneumonia followed by acute respiratory distress syndrome (ARDS) and death. This spectrum complicates treatment algorithms and underlies a critical need for rapid-response etiologic and prognostic indicators that readily inform treatment options in an outbreak setting. The overall goal of this program is to develop new platform technologies to rapidly recover and characterize new and emerging viruses in vitro and in vivo. Secondary objectives are to use functional genomics as diagnostic and prognostic indicators of virulence and disease severity following virus infection of the lung. Using a highly interactive team, we will test the hypothesis that """"""""-omics"""""""" and other physiologic signatures will: i) predict etiology;ii) provide early prognostic indicators of virulence, and iii) inform public health measures and therapeutic responses. The program uses highly pathogenic HCoV strains (severe acute respiratory syndrome coronavirus and HCoV EMC/2012) and lAV strains (H1N1 Ca/04/2009 and H1N1 1918) and various clinical isolates as models.
In Aim 1, we will develop platforms to recover novel respiratory viruses and identify diagnostic and prognostic indicators of severe lung disease by infecting primary human lung cells.
In aim 2, we use the Collaborative Cross Mice to develop new animal models of human disease and to define conserved genomic signatures that correlate with etiology and disease severity and then validate the role of these biomarkers in models of outbred human populations infected with different high and low path respiratory viruses.
In Aim 3, the goal is to use functional genomics and computational biology to not only diagnose virus etiology and forecast disease severity in the lung, but in parallel, develop a highly portable screening platform that rapidly identifies and then validates the lead compounds that attenuate disease severity in robust models of outbred human populations.

Public Health Relevance

The overall goal of this program is to develop new platform technologies that use functional genomics as diagnostic and prognostic indicators of severe end stage lung disease following virus infection of the lung. Using a highly interactive team, we will test the hypothesis that -omics and other physiologic signatures will: predict etiology;ii) provide early prognostic indicators, and iii) inform public health measures and therapeutic responses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109761-01
Application #
8655267
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
2014-03-07
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,184,414
Indirect Cost
$227,381
Name
Columbia University
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Morrison, Juliet; Rathore, Abhay P S; Mantri, Chinmay K et al. (2017) Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. J Virol 91:
Hertz, Tomer; Beatty, P Robert; MacMillen, Zachary et al. (2017) Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections. J Immunol 198:4025-4035
Johansen, Cheryl A; Williams, Simon H; Melville, Lorna F et al. (2017) Characterization of Fitzroy River Virus and Serologic Evidence of Human and Animal Infection. Emerg Infect Dis 23:1289-1299
Menachery, Vineet D; Graham, Rachel L; Baric, Ralph S (2017) Jumping species-a mechanism for coronavirus persistence and survival. Curr Opin Virol 23:1-7
Hou, Yixuan; Lin, Chun-Ming; Yokoyama, Masaru et al. (2017) Deletion of a 197-Amino-Acid Region in the N-Terminal Domain of Spike Protein Attenuates Porcine Epidemic Diarrhea Virus in Piglets. J Virol 91:
Lindesmith, Lisa C; Kocher, Jacob F; Donaldson, Eric F et al. (2017) Emergence of Novel Human Norovirus GII.17 Strains Correlates With Changes in Blockade Antibody Epitopes. J Infect Dis 216:1227-1234
Lindesmith, Lisa C; Brewer-Jensen, Paul D; Mallory, Michael L et al. (2017) Antigenic characterization of a novel recombinant GII.P16-GII.4 Sydney norovirus strain with minor sequence variation leading to antibody escape. J Infect Dis :
Wang, Jiaqi; Bardelli, Marco; Espinosa, Diego A et al. (2017) A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. Cell 171:229-241.e15
Sheahan, Timothy P; Sims, Amy C; Graham, Rachel L et al. (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:
Dutta, Mukta; Robertson, Shelly J; Okumura, Atsushi et al. (2017) A Systems Approach Reveals MAVS Signaling in Myeloid Cells as Critical for Resistance to Ebola Virus in Murine Models of Infection. Cell Rep 18:816-829

Showing the most recent 10 out of 54 publications